Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00585390 · ClinicalTrials.gov registry record · Phase 2

Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

A Phase 2 study, sponsored by University of Cincinnati.

Completed
Registry status
Phase 2
Development phase

NCT00585390: Completed Phase 2 study, sponsored by University of Cincinnati.

NCT00585390 is a Phase 2 study that has completed, run by University of Cincinnati. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00585390, a Phase 2 study, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

The purpose of this research study is to find out what effects (good and bad) that omega-3 fatty acids has on schizophrenia.

Interventions

  • DRUG Placebo
  • DIETARY_SUPPLEMENT Omega-3 Fatty Acids
  • OTHER Olive oil placebo
  • DIETARY_SUPPLEMENT EPA fish oil concentrate; DHA fish oil concentrate

Trial Details

FieldValue
Start Date 2008-01
Est. Completion 2009-11
Phase Phase 2
University of Cincinnati

245 total trials

What the finished NCT00585390 record still lists

NCT00585390 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT00585390 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00585390 about?

NCT00585390 is a clinical study titled "Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia". The purpose of this research study is to find out what effects (good and bad) that omega-3 fatty acids has on schizophrenia.

What is the current status of trial NCT00585390?

This trial is currently completed. It is a Phase 2 study. The study started on 2008-01. Estimated completion is 2009-11.

What interventions are being tested in trial NCT00585390?

The interventions under investigation include: Placebo (DRUG), Omega-3 Fatty Acids (DIETARY_SUPPLEMENT), Olive oil placebo (OTHER), EPA fish oil concentrate; DHA fish oil concentrate (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00585390?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00585390, the US trial registry maintained by the National Library of Medicine. NCT00585390 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.